患者来源异种移植模型市场－全球产业规模、份额、趋势、机会及预测（按肿瘤类型、类型、最终用户、地区和竞争细分，2020 年至 2030 年）

2024 年全球患者来源异种移植 (PDX) 模型市场价值为 22.6 亿美元，预计到 2030 年将达到 40 亿美元，预测期内复合年增长率为 9.98%。这种增长是由该模型在癌症研究和个人化医疗中不断扩大的作用所推动的。 PDX 模型是透过将人类肿瘤组织植入免疫缺陷小鼠体内而创建的，它提供了一个与人类肿瘤行为非常相似的临床相关平台，使其在研究癌症进展和评估新疗法方面具有不可估量的价值。随着全球癌症发生率的上升，对准确和预测性的临床前模型的需求变得越来越重要。 PDX 模型保留了原始肿瘤的遗传和分子特征，为研究人员评估药物疗效和开发标靶治疗提供了更精确的工具。个人化肿瘤治疗的转变，即根据患者的个人基因特征量身定制治疗方案，进一步推动了对 PDX 模型的需求。这些模型使科学家和临床医生能够测试患者肿瘤的治疗方法，预测治疗反应并推进更有效和个人化的护理策略。

关键市场驱动因素

癌症发生率上升和未满足的医疗需求

主要市场挑战

异质性和变异性

主要市场趋势

个人化医疗日益受到关注

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球病患来源异种移植模型市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依肿瘤类型（肺癌、胰臟癌、摄护腺癌、乳癌、其他癌症）
  • 按类型（小鼠、大鼠）
  • 依最终使用者（住院设定、社区设定）
  • 按公司分类（2024）
  • 按地区
• 市场地图

第六章：北美病患来源的异种移植模型市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲病患来源的异种移植模型市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区人源异种移植模型市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美洲患者来源的异种移植模型市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲病患来源的异种移植模型市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章： 大环境分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• Charles River Laboratories Inc.
• The Jackson Laboratory
• Crown Bioscience,Inc.
• Altogen Labs
• Envigo
• WuxiAppTec
• Oncodesign
• Hera BioLabs
• XenTech
• Abnova Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global Patient-Derived Xenograft (PDX) Model Market was valued at USD 2.26 billion in 2024 and is projected to reach USD 4.00 billion by 2030, growing at a CAGR of 9.98% during the forecast period. This growth is being driven by the model's expanding role in cancer research and personalized medicine. PDX models, created by implanting human tumor tissue into immunodeficient mice, offer a clinically relevant platform that closely mirrors human tumor behavior, making them invaluable in studying cancer progression and evaluating new therapies. As global cancer incidence rises, the need for accurate and predictive preclinical models becomes increasingly critical. PDX models preserve the genetic and molecular characteristics of original tumors, offering researchers a more precise tool for evaluating drug efficacy and developing targeted treatments. The shift towards personalized oncology, which tailors therapies to the individual genetic profiles of patients, is further boosting demand for PDX models. These models enable scientists and clinicians to test therapies on patient-derived tumors, predicting treatment responses and advancing more effective and individualized care strategies.

Key Market Drivers

Rising Cancer Incidence and Unmet Medical Needs

The increasing global burden of cancer is a key factor fueling the growth of the PDX model market. With cancer expected to see a 70% increase in new cases over the next two decades, the urgency for innovative treatment options has intensified. PDX models replicate the complexity and heterogeneity of human tumors, making them ideal for understanding tumor biology and testing therapeutic agents. These models maintain critical aspects of patient tumors-such as genetic diversity, microenvironment interactions, and treatment resistance-allowing researchers to evaluate treatment outcomes with greater accuracy. As cancer research shifts towards precision-based therapies, the utility of PDX models in identifying and validating new drug candidates has become even more pronounced. Their ability to model real-world tumor behavior supports drug development pipelines and helps address significant unmet medical needs.

Key Market Challenges

Heterogeneity and Variability

Despite their advantages, PDX models face limitations due to the inherent heterogeneity of human tumors. Tumor samples differ significantly between patients, even within the same cancer type, complicating efforts to create universally representative models. This variability can influence drug response outcomes, affecting the reliability of data and complicating clinical translation. While PDX models retain many biological features of the original tumors, they cannot capture the full extent of molecular and cellular complexity. Furthermore, the engraftment process itself may alter tumor characteristics over time. These limitations highlight the need for ongoing refinement in PDX model development to ensure broader applicability and predictive accuracy in therapeutic evaluation.

Key Market Trends

Rising Interest in Personalized Medicine

The growing adoption of personalized medicine is a major trend shaping the PDX model market. Personalized treatment strategies require models that can mimic patient-specific tumor biology. PDX models allow for the creation of "avatar mice"-animal models implanted with tumor samples from individual patients-which are used to test a range of therapeutic options. These models help clinicians determine the most effective course of treatment, reducing adverse effects and improving outcomes. The integration of PDX models into clinical research has accelerated drug development and enhanced the success rate of oncology trials by providing patient-relevant data. As the pharmaceutical industry increasingly embraces targeted therapies, PDX models are expected to play a crucial role in refining therapeutic selection and reducing trial-and-error approaches in cancer treatment.

Key Market Players

• Charles River Laboratories Inc.
• The Jackson Laboratory
• Crown Bioscience, Inc.
• Altogen Labs
• Envigo
• WuxiAppTec
• Oncodesign
• Hera BioLabs
• XenTech
• Abnova Corporation

Report Scope:

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Patient-Derived Xenograft Model Market, By Tumor Type:

• Lung Cancer
• Pancreatic Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer

Patient-Derived Xenograft Model Market, By End User:

• Inpatient Settings
• Community Settings

Patient-Derived Xenograft Model Market, By Type:

• Rats
• Mice

Patient-Derived Xenograft Model Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

Global Patient-Derived Xenograft Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Patient-Derived Xenograft Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)
  • 5.2.2. By Type (Mice, Rats)
  • 5.2.3. By End-User (Inpatient Settings, Community Settings)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Patient-Derived Xenograft Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Type
  • 6.2.3. By End-user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Patient-Derived Xenograft Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-user
  • 6.3.2. Mexico Patient-Derived Xenograft Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-user
  • 6.3.3. Canada Patient-Derived Xenograft Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-user

7. Europe Patient-Derived Xenograft Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Type
  • 7.2.3. By End-user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Patient-Derived Xenograft Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-user
  • 7.3.2. Germany Patient-Derived Xenograft Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-user
  • 7.3.3. United Kingdom Patient-Derived Xenograft Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-user
  • 7.3.4. Italy Patient-Derived Xenograft Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-user
  • 7.3.5. Spain Patient-Derived Xenograft Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-user

8. Asia-Pacific Patient-Derived Xenograft Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Type
  • 8.2.3. By End-user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Patient-Derived Xenograft Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-user
  • 8.3.2. India Patient-Derived Xenograft Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-user
  • 8.3.3. South Korea Patient-Derived Xenograft Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-user
  • 8.3.4. Japan Patient-Derived Xenograft Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-user
  • 8.3.5. Australia Patient-Derived Xenograft Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-user

9. South America Patient-Derived Xenograft Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Type
  • 9.2.3. By End-user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Patient-Derived Xenograft Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-user
  • 9.3.2. Argentina Patient-Derived Xenograft Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-user
  • 9.3.3. Colombia Patient-Derived Xenograft Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-user

10. Middle East and Africa Patient-Derived Xenograft Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Type
  • 10.2.3. By End-user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Patient-Derived Xenograft Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-user
  • 10.3.2. Saudi Arabia Patient-Derived Xenograft Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-user
  • 10.3.3. UAE Patient-Derived Xenograft Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Charles River Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. The Jackson Laboratory
• 15.3. Crown Bioscience,Inc.
• 15.4. Altogen Labs
• 15.5. Envigo
• 15.6. WuxiAppTec
• 15.7. Oncodesign
• 15.8. Hera BioLabs
• 15.9. XenTech
• 15.10. Abnova Corporation

16. Strategic Recommendation

17. About Us & Disclaimer